Three topical ophthalmic formulations designed to treat presbyopia demonstrated positive results in the phase 2 VIVID clinical trial, Visus Therapeutics announced in a press release.
Based on these results, the company is planning to start phase 3 pivotal trials.
The trial compared the safety and efficacy of fixed-dose combinations of Brimochol and Brimochol F (carbachol and brimonidine tartrate) and a similarly formulated preservative-free carbachol in 85 patients, aged 45 to 80 years, with emmetropic phakic and pseudophakic presbyopia at three U.S. centers.
For all formulations, at least 83%